Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › SLS

SELLAS Life Sciences Group

SLS Lead: Phase 3 7 Biotech Distilled articles ↓ 21 filings & releases ↓ Cash $138M (Jun 30, 2026) ↓ 7 verdicts ↓ 1 timing quote ↓
Oncology PeptideSmall Molecule

Market cap $1.70B 201.9M shares (10-Q, Aug 10, 2026) × $8.42 close Nov 6, 2026

Most recent annual filing: 2026-03-15

Catalyst timeline

2 trackedQuarter catalyst calendar →
  1. SLS009 AML Ph2 topline4Q 2026SLS009 AML Ph2 topline, 4Q 2026, material
  2. SLS009 Tambiciclib readoutDec 14, 2026SLS009 Tambiciclib readout, Dec 14, 2026, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (9 active programs)

Capital (as filed)

Cash
$138M cash and cash equivalents · Jun 30, 2026 (10-Q)
Operating cash flow
−$7.6M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$138M cash per the update of Oct 28, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (7)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (7 calls)

Every verdict Biotech Distilled has published on SELLAS Life Sciences Group, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2025-12-29 Watch SELLAS Life Sciences (SLS): Scientific Due Diligence for Lead and Pipeline Products Binary event gamble on GPS Phase 3 REGAL readout with SLS009 as a scientifically stronger backstop; watch list given open-label risk and near-100% peptide vaccine failure rate in Phase 3.
  2. 2026-03-14 Hold UPDATE: SELLAS (SLS) - Checking the Boxes on the SLS009 Pivot and Cash Runway SLS009 Phase 2 dosed on time and financing risk eliminated; thesis intact as REGAL binary readout remains the main event.
  3. 2026-03-22 Hold UPDATE: SELLAS (SLS) - SEC Filings, Cash Runways, and a Peek at the Mechanism Financial runway confirmed at ~$114M pro-forma cash, SLS009 mechanism strengthening, but REGAL binary readout still the primary catalyst requiring patience.
  4. 2026-05-12 Hold UPDATE: SELLAS (SLS) - Two Events From the Bell REGAL is two events from unblinding with fortress cash of ~$114.6M; the binary is imminent and position sizing matters more than direction.
  5. 2026-07-28 Watch UPDATE: SELLAS Life Sciences (SLS) - The Stock Doubled, the Arbitration Died, and the Cash Grew Stock doubled to $10.84 with no data released, compressing the risk/reward materially; chasing a doubled price into an open-label vaccine readout is a different bet, and new money no longer gets a 'free look at the data.'
  6. 2026-08-12 Watch UPDATE: SELLAS Life Sciences (SLS) - Three Months, Zero Events REGAL still at 78/80 events after three months of silence; balance sheet is a fortress but the stock has doubled while science hasn't moved, making the coin flip more expensive with an indefinite readout window.
  7. 2026-10-29 Watch UPDATE: SELLAS Life Sciences (SLS) - Event #80 Is In Event #80 reached triggering database lock with topline guided by year-end; scientific risk fully intact with open-label design and near-100% peptide vaccine failure rate, while asymmetry has worsened at ~$10 vs. spring entry.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (1 quote from 1 filing)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (21)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 11, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

7 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)